Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedApr 26, 2024
DataAggregated Company Financials
Companies6
  • 7D-8.0%
  • 3M10.2%
  • 1Y3.9%
  • YTDn/a

Over the last 7 days, the Biotech industry has dropped 8.0%, driven by Idorsia declining 11%. This takes the industry's 12 month performance to a gain of 3.9%. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Apr 2024CHF394.2mCHF67.2m-CHF172,318,778.620.1x-2.3x5.9x
Sun, 24 Mar 2024CHF340.9mCHF67.3m-CHF173,226,506.340.2x-2x5.1x
Tue, 20 Feb 2024CHF400.8mCHF55.5m-CHF173,220,198.621x-2.3x7.2x
Thu, 18 Jan 2024CHF344.4mCHF317.7m-CHF175,983,810.000.6x-2x1.1x
Sat, 16 Dec 2023CHF298.2mCHF317.8m-CHF208,848,298.00n/a-1.4x0.9x
Mon, 13 Nov 2023CHF292.3mCHF318.5m-CHF211,286,620.00n/a-1.4x0.9x
Wed, 11 Oct 2023CHF251.6mCHF318.4m-CHF213,238,640.00n/a-1.2x0.8x
Fri, 08 Sep 2023CHF298.1mCHF318.6m-CHF188,945,875.00n/a-1.6x0.9x
Sun, 06 Aug 2023CHF528.8mCHF323.7m-CHF180,059,754.00n/a-2.9x1.6x
Tue, 04 Jul 2023CHF308.8mCHF330.8m-CHF180,800,170.00n/a-1.7x0.9x
Thu, 01 Jun 2023CHF312.0mCHF334.0m-CHF183,619,507.00n/a-1.7x0.9x
Sat, 29 Apr 2023CHF365.2mCHF498.8m-CHF18,436,101.001.6x-19.8x0.7x
Mon, 27 Mar 2023CHF426.5mCHF497.1mCHF11.5m1.5x37x0.9x
Wed, 22 Feb 2023CHF474.3mCHF493.4mCHF14.5m1.6x32.7x1x
Fri, 20 Jan 2023CHF521.2mCHF493.4mCHF14.5m1.8x35.9x1.1x
Sun, 18 Dec 2022CHF500.1mCHF493.4mCHF14.5m1.7x34.5x1x
Tue, 15 Nov 2022CHF537.5mCHF493.2mCHF15.0m1.8x35.8x1.1x
Thu, 13 Oct 2022CHF515.9mCHF510.2mCHF15.9m1.9x32.5x1x
Sat, 10 Sep 2022CHF517.7mCHF496.2mCHF27.8m1.8x18.6x1x
Mon, 08 Aug 2022CHF534.3mCHF487.8mCHF42.2m2x12.6x1.1x
Wed, 06 Jul 2022CHF537.3mCHF457.9mCHF81.3m2.1x6.6x1.2x
Fri, 03 Jun 2022CHF649.0mCHF468.5mCHF24.7m2.1x26.2x1.4x
Sun, 01 May 2022CHF725.5mCHF299.6m-CHF141,437,692.001.9x-5.1x2.4x
Tue, 29 Mar 2022CHF1.2bCHF286.0m-CHF138,938,782.002x-8.8x4.3x
Thu, 24 Feb 2022CHF1.3bCHF281.6m-CHF139,054,314.002x-9.2x4.5x
Sat, 22 Jan 2022CHF5.3bCHF315.6m-CHF659,277,194.001.5x-8x16.8x
Mon, 20 Dec 2021CHF4.1bCHF318.2m-CHF658,912,125.001.5x-6.2x12.9x
Wed, 17 Nov 2021CHF4.0bCHF318.0m-CHF658,936,363.001.5x-6.1x12.7x
Fri, 15 Oct 2021CHF4.7bCHF294.2m-CHF585,251,048.002.3x-8x15.9x
Sun, 12 Sep 2021CHF5.1bCHF305.7m-CHF612,309,374.801.3x-8.4x16.8x
Tue, 10 Aug 2021CHF5.5bCHF306.0m-CHF612,309,374.801.1x-8.9x17.8x
Mon, 03 May 2021CHF5.5bCHF352.3m-CHF535,605,963.801.1x-10.4x15.7x
Price to Earnings Ratio

-10.4x


Total Market Cap: CHF5.5bTotal Earnings: -CHF535,605,963.80Total Revenue: CHF352.3mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average 5.1x202220232024
Current Industry PE
  • Investors are relatively neutral on the Swiss Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 5.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 42% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Swiss Biotech compare with similar industries?

CH Market0.027%
Healthcare2.22%
Biotech-7.96%
Biotech-7.96%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SANN Santhera Pharmaceuticals HoldingCHF9.501.4%
+CHF1.2m
50.8%PS1.6x
SPEX SpexisCHF0.05914.0%
+CHF487.2k
-85.0%PS3.4x
OBSN ObsEvaCHF0.00620.0%
+CHF117.2k
-93.2%PE0.1x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

SANN

CHF9.50

Santhera Pharmaceuticals Holding

7D

1.4%

1Y

50.8%

MOLN

CHF3.20

Molecular Partners

7D

-4.5%

1Y

-44.3%

ADXN

CHF0.12

Addex Therapeutics

7D

-27.9%

1Y

1.8%

KURN

CHF6.89

Kuros Biosciences

7D

-8.6%

1Y

373.5%

SPEX

CHF0.059

Spexis

7D

14.0%

1Y

-85.0%

OBSN

CHF0.006

ObsEva

7D

20.0%

1Y

-93.2%

RLF

CHF1.25

Relief Therapeutics Holding

7D

-0.8%

1Y

-81.6%